Drug · CHEMBL802
MINOXIDIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MINOXIDIL. Drugs and targets, record CHEMBL802. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL802
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Loniten, Lonolox, Men's rogaine, Minodyl, Minoxidil (for men), Minoxidil (for women), Minoxidil extra strength (for men), Regaine for men, Regaine for women, Riup, Rogaine, Rogaine (for men), Rogaine (for women), Rogaine extra strength (for men), Theroxidil, Women's rogaine
- ChEMBL
- Other names
- Alopexil, Alostil, Minoximen, Mintop, NSC-757106, Normoxidil, Pierminox, Prexidil, Tricoxidil, U-10,858, U-10858
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 14 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ABCC9 | Sulfonylurea receptor 2, Kir6.2 | Sulfonylurea receptor 2, Kir6.2 opener | OPENER | https://conductscience.org/library/genes/10060 |
| KCNJ11 | Sulfonylurea receptor 2, Kir6.2 | Sulfonylurea receptor 2, Kir6.2 opener | OPENER | https://conductscience.org/library/genes/3767 |
Source ChEMBL
Diseases14
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 14Source Open Targets
See all 14 diseasesTrials81
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01226459 | Clinical Trial in Females for Female Pattern Hair Loss | Phase 3 | 404 | 2014-06-03 | minoxidil | Its name | ClinicalTrials.gov |
| NCT01145625 | Clinical Trial in Females With Female Pattern Hair Loss | Phase 3 | 322 | 2014-04-25 | minoxidil | Its name | ClinicalTrials.gov |
| NCT01325337 | Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia | Phase 2 | 307 | 2014-04-10 | minoxidil | Its name | ClinicalTrials.gov |
| NCT02460289 | Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia | 63 | 2023-08-01 | minoxidil | Its name | ClinicalTrials.gov | |
| NCT02460497 | Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia | 61 | 2023-08-01 | minoxidil | Its name | ClinicalTrials.gov | |
| NCT03753113 | Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% | Phase 3 | 24 | 2020-03-16 | minoxidil | Its name | ClinicalTrials.gov |
| NCT00876200 | Efficacy of Minoxidil in Children With Williams-Beuren Syndrome | Phase 2 | 21 | 2019-07-26 | minoxidil | Its name | ClinicalTrials.gov |
| NCT03488108 | Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women | Phase 1/2 | 20 | 2020-04-08 | minoxidil | Its name | ClinicalTrials.gov |
| NCT00607477 | Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension | 2 | 2011-02-16 | minoxidil | Its name | ClinicalTrials.gov | |
| NCT05888922 | Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia | Phase 3 | 520 | minoxidil | Its name | ClinicalTrials.gov |
1 to 10 of 81
See all 81 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Minoxidil Foam vs Vehicle Foam: serious adverse events | 6 of 203 | 4 of 201 | 404 | NCT01226459 | Trial comparisons |
| 2% MTS vs 5% MTF: serious adverse events | 8 of 161 | 2 of 161 | 322 | NCT01145625 | Trial comparisons |
| Platelet Rich Plasma vs Minoxidil Foam: Adverse Event of Swelling on Scalp | 0 of 19 | 0 of 19 | 38 | NCT03488108 | Trial comparisons |
| Platelet Rich Plasma vs Minoxidil Foam: Adverse Event of Redness on Scalp | 0 of 19 | 0 of 19 | 38 | NCT03488108 | Trial comparisons |
| Platelet Rich Plasma vs Minoxidil Foam: deaths from any cause | 0 of 19 | 0 of 18 | 37 | NCT03488108 | Trial comparisons |
| Platelet Rich Plasma vs Minoxidil Foam: serious adverse events | 0 of 19 | 0 of 18 | 37 | NCT03488108 | Trial comparisons |
| Treatment Group vs Control Group: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT03753113 | Trial comparisons |
| Treatment Group vs Control Group: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT03753113 | Trial comparisons |
| Minoxidil vs Placebo: serious adverse events | 1 of 9 | 1 of 12 | 21 | NCT00876200 | Trial comparisons |
Papers from its trials44
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL802
GET https://conductscience.org/api/drugs/v1/CHEMBL802/trials?page=2